SCHEMBL1391600

SCHEMBL1391600

Cc1ccc(CNc2nc(Nc3ccc(F)c(C(F)(F)F)c3)nc(OCC(F)(F)F)n2)o1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ STK17A Q9UEE5 3/20 0.43
▸ CFTR P13569 5/20 0.42
▸ JAK2 O60674 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ JAK1 P23458 1/20 0.40
▸ JAK3 P52333 1/20 0.40
▸ STK17B O94768 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ TDO2 P48775 4/20 0.36
▸ KCNH3 Q9ULD8 1/20 0.34
▸ HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1391075 0.92 MAPT (0.45) MEN1KMT2ALMNATDP1STK17A
SCHEMBL1391463 0.86 APP (0.46) MEN1KMT2ALMNASTK17AJAK2
SCHEMBL1390950 0.85 LMNA (0.50) MEN1KMT2ALMNATDP1L3MBTL1
SCHEMBL1391235 0.84 LMNA (0.48) MEN1KMT2ALMNATDP1L3MBTL1
SCHEMBL1391653 0.83 LMNA (0.52) MEN1KMT2ALMNATDP1L3MBTL1
SCHEMBL1391473 0.83 LMNA (0.50) MEN1KMT2ALMNATDP1L3MBTL1
SCHEMBL1391489 0.82 MEN1 (0.43) MEN1KMT2ALMNATDP1L3MBTL1
SCHEMBL1391160 0.82 LMNA (0.49) MEN1KMT2ALMNATDP1L3MBTL1
SCHEMBL1392125 0.81 MEN1 (0.42) MEN1KMT2ALMNATDP1L3MBTL1
SCHEMBL1391343 0.81 CFTR (0.46) MEN1KMT2ALMNATDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 — — US disclosed
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 — — US disclosed
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof PROGENICS PHARMACEUTICALS, INC. (US) 2012-01-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120009151-A1 Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof HAVCR2, ZC3HAV1, MAVS MEN1 4840/4885KMT2A 4066/4885LMNA 3218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback